AUSTIN, TX, and HAMILTON, ON, March 13, 2019 – Triumvira Immunologics, Inc., (Triumvira) a privately held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, today announced the appointment of Cynthia Molina as Vice President of Regulatory Affairs. In this position, Cynthia will be responsible for global regulatory strategic development, oversight of regulatory submissions, and interactions with US and international governmental health authorities.

Before joining Triumvira, Ms. Molina was most recently VP of Global Regulatory Affairs at Cell Medica, Inc in Houston, TX, for 6 years and accumulated 30 years of experience in multiple facets of product development for pharmaceutical, biotechnology, biologic, and in vitro diagnostic products, with a primary focus on regulatory affairs. In addition to regulatory affairs, her experience includes clinical and preclinical strategic planning, quality assurance, process development and manufacturing for oncology and infectious disease products. Ms. Molina has experience leading preparation of a variety of global regulatory submissions, including INDs, NDAs, BLAs, MAAs, global CTAs, 510Ks, PMAs, orphan and Fast Track submissions, and clinical study reports. She has held management positions at both large and small corporations, including Abbott Laboratories.

Paul Lammers, MD, MSc., President and CEO of Triumvira commented, “We are very pleased to welcome Cynthia to our management team. Her background and experience in regulatory affairs will enhance our interactions with regulatory agencies supporting our plan to bring multiple TAC product candidates into clinical development alone, as well as in collaboration with our business partners.”

Additionally, several Triumvira executives are presenting at upcoming conferences. Triumvira Chief Technology Officer Donna Rill and Senior Vice President of R&D Dr. Andreas Bader will present at CellCAN’s Second Annual, Pan-Canadian Strategic Forum on Regenerative Medicine and Cell Therapy, to be held March 13-15, 2019, in Toronto, ON. Director of R&D and Head of Platform Development Dr. Christopher Helsen will present at the 26th International Molecular Med Tri-Conference on March 14, 2019, in San Francisco, CA. Topics of their presentations will be:

Characterizing products for GMP manufacturing: What, how and when? (Ms. D. Rill)

Optimizing cell and gene therapy manufacturing, Planning for Success – the path to commercialization (Ms. D. Rill)

TAC technology, its unique and novel MoA, preclinical data and considerations for biomarker analysis in our Phase I/II trial (Dr. A. Bader)

Development of a CD19-TAC therapy for a first in human phase I study (Dr. C. Helsen)

Triumvira also announces Joshua Carle, Vice President of Business Development, will attend the Bio-Europe Spring Partnering conference in Vienna, Austria from March 25–27, 2019. Mr. Carle and Triumvira are seeking to find out-licensing partners to accelerate our TAC pipeline development, collaborators with novel cancer cell surface antigens looking to expand into engineered T-cells, and to identify immuno-oncology assets that are complementary to our TAC T-cell platform.

About Triumvira Immunologics

Triumvira Immunologics, Inc. (Triumvira) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are in Austin, Texas, and our research facilities in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to partners@triumvira.com.

Contact
Triumvira Immunologics Inc.
LaVoieHealthScience
Katie Gallagher
Phone: +1-617-374-8800, Ext. 109
kgallagher@lavoiehealthscience.com
www.triumvira.com
partners@triumvira.com

Dr. Paul Lammers
President & Chief Executive Officer

Triumvira Immunologics
www.triumvira.com

Interview conducted by:
Lynn Fosse, Senior Editor, CEOCFO Magazine, Published – March 4, 2019

CEOCFO: Dr. Lammers, you have been president and CEO for a little over a year now. What attracted you to Triumvira Immunologics, Inc?
Dr. Lammers: When I started to look at my next opportunity, I came across a number of companies and was really intrigued by the Triumvira technology. Given the fact that CAR-T therapy is about the hottest area in immune-oncology, and the TAC technology is very well differentiated from CAR-T cells and invented by a very reputable professor at McMaster University in Hamilton, Ontario. I thought, “Man, would it not be great to build a company around this technology and bring this technology into the clinic for patients.”

CEOCFO: What has happened over the last year at Triumvira? How are you leading the charge?
Dr. Lammers: When I joined on January 1st of 2018 there were two full-time Triumvira scientists up in Hamilton at Dr. Bramson’s lab. Right now, we have fourteen. The typical conundrum in biotech is that “you need a team to raise the money and you need money to raise the team”. Therefore, I told the board of directors, “If you want me build the team, then get ready, because I will build the team.” I then started to build the team and hired the best people in T-Cell therapy that I could find, no matter where they lived. We have an R&D group in Hamilton, Ontario that we moved out of the academic labs into a separate lab facility there. Then we opened a corporate headquarters here in Austin, Texas, where we have six people. Then we have a number of experienced professionals around the country, from Miami, to Seattle, to Houston. So far it is working very well, and a great deal of progress has been made! We had a great pre-IND meeting with FDA last December. We are moving our pipeline forward and aim to have our first IND submitted in March, which means that we could have our first patients treated with our technology in the middle of the year. Then we will move our second program forward into the IND-stage later this year. We also expanded our Board of Directors. We brought in two very strong independent directors with a lot of experience in oncology and cell therapy. Therefore, it has been a fantastic ride so far!

CEOCFO: What, if any, are the challenges of collaboration in science when you are working remotely? What have you learned over this year about how to do that successfully?
Dr. Lammers: I think the two critical components for any business are information and communication. I think that when you have a semi-virtual business model, it requires you to be more informative and communicate more often. Therefore, we have our weekly management team calls, and every other week we have a teleconference with the whole team. I want to make sure that the R&D group in Hamilton knows that there is a management team to support them, and so members of the management team try to spend two to three days a month up in Hamilton to make sure that we have presence and visibility. That is important, because for me, leadership is visibility to a large extent as well. I want to make sure that they realize that we come to work every day and we work hard to make things happen. So far it has been going really well.

Read Complete Article

MONTREAL and AUSTIN, Texas and HAMILTON, Ontario, Feb. 20, 2019 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative pharmaceutical products, today announced it has entered into a secured loan and exclusive License Agreement with privately-held Triumvira Immunologics Inc. (“Triumvira”). The US$5 million secured loan has a term of 1 year and will enable Triumvira to accelerate activities to bring its innovative lead program into the clinic. In addition, Triumvira shall grant Knight an exclusive license to commercialize Triumvira’s future approved products for Canada, Israel, Mexico, Colombia and for TAC01-CD19 for Israel, Mexico, Brazil and Colombia.

“We are excited to help Triumvira accelerate development of their novel platform for engineering T cells to attack cancer,” said Jonathan Ross Goodman, Chief Executive Officer of Knight.

“We are thrilled both with this Knight solution to our short-term funding need and in having Knight as our proven successful Canadian, Israeli and South American distribution partner,” said Dr. Paul Lammers, President and Chief Executive Officer.

Read Complete Article

AUSTIN, Texas, and HAMILTON, Ontario, January 29, 2019 – Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced that Dr. Paul Lammers, President & CEO, will both present and moderate a round table discussion at the CAR-T Congress EU, to be held in London UK on January 30-31. The invitations acknowledge Triumvira’s expertise in the novel engineering of T cells for the potential treatment of hematological malignancies and solid tumors.

The CAR-T Congress EU is a forum focused on discovering, translating, developing, and commercializing CAR-T into viable and accessible therapies. CAR-T cell therapies have shown transformational activity in hematological malignancies. However, despite the tremendous success so far, there are still hurdles to overcome before CAR-T can be effective in mainstream oncology beyond hematological malignancies. The European CAR-T Congress’ mission is to address the opportunities and challenges that presently face the CAR-T field and maximize the potential of this ground-breaking therapy. As Triumvira’s proprietary T cell Antigen Coupler (TAC) technology is biologically distinct from CAR-T and has the potential to be a next-generation solution, Triumvira seeks to address some of the challenging areas for existing therapies in hematological malignancies and expand treatment activity to solid tumors.

Paul Lammers, MD, MSc, President, and Chief Executive Officer will present and lead a round table discussion at CAR-T Congress EU as follows:

Date: Wednesday, January 30, 2019

Time: 14:20 (GMT)

Venue: Millennium Gloucester Hotel, 4-18 Harrington Gardens, Kensington, London, SW7 4LH

Presentation: Triumvira’s TAC-T cell Technology: A Step Forward in Adoptive T Cell Therapy.

Date: Thursday, January 31, 2019

Time: 10:30 (GMT)

Venue: Millennium Gloucester Hotel, 4-18 Harrington Gardens, Kensington, London, SW7 4LH

Moderating Round Table: Critical Challenges Facing CAR-T Therapy: Strengthening CAR-T for Solid Tumors.

About Triumvira Immunologics
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are in Austin, Texas, and our research facilities in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to partners@triumvira.com

Triumvira Contact
LaVoieHealthScience
Katie Gallagher
Phone: +1-617-374-8800, Ext. 109
kgallagher@lavoiehealthscience.com

AUSTIN, Texas & HAMILTON, Ontario & TORONTO – AUSTIN, Texas, and HAMILTON, Ontario, January 23, 2019 – Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointments of Andreas Bader as Senior Vice President of Research & Development, and Joshua Carle as Vice President of Business Development.

Dr. Andreas Bader joined Triumvira in 2018. Dr. Bader is a seasoned biotech executive with more than 20 years’ experience in oncology drug discovery and development, and business and research strategies. Previously, Dr. Bader acted as Co-Founder and CEO of Orros Biotherapeutics LLC, and as a scientific Co-Founder of Mirna Therapeutics, Inc., where he held multiple leading positions in R&D and led research programs from discovery to the completion of Phase 1 clinical trial. Prior to Mirna, Dr. Bader functioned as the Scientific Lead of the microRNA therapeutics program at Asuragen, Inc. Dr. Bader completed his post-doctoral training at The Scripps Research Institute, La Jolla, California, received his Ph.D. in Biochemistry and his MSc degree in Biology from the University of Innsbruck, Austria.

Joshua Carle, MBA, is a cross-functional executive with over 15 years of strategic transaction and R&D investment experience while in Management Consulting and BioPharma. Mr. Carle has led or advised more than fifty potential strategic transactions, resulting in the successful execution of greater than $2 billion in disclosed deal value and committed R&D funds. Mr. Carle joins from Pfizer Inc., where he drove BD strategy, commercial assessments, and broad transaction support for licensing/M&A efforts for Pfizer Oncology. Previously, Mr. Carle held roles of increasing responsibility in business development activities at Daiichi Sankyo Inc. and Clearview Projects Inc., a strategic advisory firm focused on licensing/M&A for the BioPharma industry. Mr. Carle received his undergraduate degree in Economics from the University of Pennsylvania and MBA from the Villanova School of Business.

Paul Lammers, MD, MSc., President and CEO of Triumvira Immunologics commented, “The addition of Andy and Josh brings two seasoned professionals to our company, which will help us tremendously as we build Triumvira into a significant player in the exciting and rapidly expanding field of engineered T-cell therapy in immuno-oncology. I am looking forward to their many contributions as we bring our TAC product candidates into clinical development and ultimately towards commercialization, alone as well as in collaboration with our business partners.”

About Triumvira Immunologics
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, with our research facilities in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to partners@triumvira.com

Triumvira Contact
LaVoieHealthScience
Katie Gallagher
Phone: +1-617-374-8800, Ext. 109
kgallagher@lavoiehealthscience.com

AUSTIN, Texas & HAMILTON, Ontario & TORONTO – Triumvira Immunologics Inc., announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week for healthcare investors at the Hilton San Francisco Union Square.

Paul Lammers, MD, MSc, President and Chief Executive Officer, will present at Biotech Showcase™ as follows:

Date: Monday, January 7, 2019
Time: 1:45PM (PST)
Room: Franciscan D, Level Ballroom
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San
Francisco, CA (United States)
Presentation: Triumvira Immunologics Company Overview and Progress in Key Programs/Technology

Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

“We are delighted that Triumvira Immunologics will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. We are thrilled to, once again, be hosting what we believe will be the great strategic networking opportunity of 2019.”

About Biotech Showcase™
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its eleventh year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

About Triumvira Immunologics
Triumvira Immunologics, Inc. is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., a niche life-sciences investment bank, with the vision of developing novel T cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with either solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are in Austin, Texas, and our research facilities are in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to partners@triumvira.com

Triumvira Contact
LaVoieHealthScience
Katie Gallagher
Phone: +1-617-374-8800, Ext. 109
kgallagher@lavoiehealthscience.com

AUSTIN, Texas & HAMILTON, Ontario & TORONTO–(BUSINESS WIRE)–Triumvira Immunologics Inc. (Triumvira), announced the presentation of key preclinical data at the American Society of Hematology (ASH) 60th Annual Meeting and Exposition, held December 1-4, 2018, in San Diego, CA. The data show that TAC-engineered T cells provide long-lasting tumor rejection in mouse models of BCMA-positive and CD19-positive hematological malignancies and suggest the presence of persisting TAC-T cells that protect against tumor regrowth upon tumor rechallenge.

The results build on data recently published in Nature Communications (Helsen et al., 2018) describing the proprietary T cell Antigen Coupler (TAC) technology, a chimeric receptor that co-opts the endogenous T cell receptor (TCR) for T cell activation and tumor cell killing. The new data, presented during a podium presentation and a poster presentation, now describe additional preclinical pharmacology of the company’s therapeutic programs in multiple myeloma (BCMA) and B-cell lymphoma (CD19). A CD19-directed TAC-T cell product is expected to enter clinical testing in H1 2019.

The podium presentation, presented by Ksenia Bezverbnaya, BSc., McMaster University, (Publication 3267: T cell engineered with a novel chimeric receptor demonstrate durable in vivo efficacy against disseminated multiple myeloma) focused on two TAC constructs each of which was fused to a different BCMA binder. A single dose of TAC-T cells (106) engineered with either construct cured mice with disseminated KMS-11 multiple myeloma cells and protected mice, in remission for 3 months after treatment, against tumor regrowth upon a fresh inoculation of tumor cells.

The poster presentation, presented by Christopher Helsen, Ph.D., Director of Research & Development, and Head of Platform Development at Triumvira (Publication 962: T cells engineered with T cell antigen coupler (TAC) receptors for haematological malignancies) described the preclinical pharmacology of TAC-T cells directed against the CD19 and BCMA antigens in multiple models of CD19-positive leukemia and lymphoma and the BCMA-positive KMS-11 multiple myeloma model. TAC-T cells specific for either antigen produced long-lasting tumor rejection and effectively protected mice in tumor rechallenge experiments indicating the presence of persisting TAC-T cells.

“These data provide further evidence that TAC furnishes T cells with properties that are highly desirable attributes for future T cell therapies,” states Dr. Paul Lammers, President & CEO of Triumvira, “TAC-T cells demonstrate superiority over 2nd generation CAR-T cells, and effectively rids animals from cancer in the absence of notable toxicities and protects these animals for a prolonged period of time. These new data further strengthens the argument for bringing the TAC technology to patients.”

About Triumvira Immunologics

Triumvira Immunologics, Inc. is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., a niche life-sciences investment bank, with the vision of developing novel T cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with either solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, and our research facilities are in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to partners@triumvira.com

Triumvira Contact
LaVoieHealthScience
Katie Gallagher
Phone: +1-617-374-8800, Ext. 109
kgallagher@lavoiehealthscience.com

AUSTIN, Texas & HAMILTON, Ontario & TORONTO—Triumvira Immunologics Inc. (Triumvira), announced the upcoming presentation of key preclinical data at the American Society of Hematology (ASH) 60th Annual Meeting and Exposition, December 1-4, 2018, in San Diego, CA. The data will be presented during a poster presentation on Sunday, December 2, and a podium presentation on Monday, December 3.

“We continue to expand our knowledge base on the promise of our proprietary T cell Antigen Coupler (TAC) technology in different tumor types,” commented Andreas Bader, Ph.D., Triumvira’s Senior Vice President of R&D. “The presentations will focus on experiments using T cells genetically engineered with TACs directed against either CD19 or BCMA antigen, demonstrating robust cell-killing and anti-tumor efficacy in preclinical models of hematological malignancies with no detectable side effects.”

Podium Presentation Title:
T Cells Engineered with a Novel Chimeric Receptor Demonstrate Durable In Vivo Efficacy Against Disseminated Multiple Myeloma

Publication Number: 962; Session Name: 703. Adoptive Immunotherapy: Preclinical Studies to Improve Safety and Efficacy of CAR-T Cells; Presentation Date/Time: Monday, December 3, 2018: 4:30 – 6:00 PM PST

Presenter: Ksenia Bezverbnaya, McMaster University

Poster Title:
T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors for Haematological Malignancies

Publication Number: 3267; Session Name: 653. Myeloma: Therapy, excluding Transplantation: Poster II; Presentation Date/Time: Sunday, December 2, 2018: 6:00 PM – 8:00 PM PST

Presenter: Dr. Christopher Helsen, Director of Research & Development, and Head of Platform Development, Triumvira Immunologics.

About Triumvira Immunologics
Triumvira Immunologics, Inc. is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., a niche life-sciences investment bank, with the vision of developing novel T cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with either solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, and our research facilities are in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to partners@triumvira.com

Triumvira Contact
LaVoieHealthScience
Katie Gallagher
Phone: +1-617-374-8800, Ext. 109
kgallagher@lavoiehealthscience.com

AUSTIN, Texas & HAMILTON, Ontario & TORONTO–(BUSINESS WIRE)–The Centre for the Commercialization of Antibodies and Biologics (CCAB) and Triumvira Immunologics, Inc. (Triumvira), announced today a new licensing agreement between the University of Toronto (U of T) and Triumvira. The agreement provides Triumvira with an exclusive license for antibodies discovered at the U of T on specified therapeutic targets. Triumvira is a privately held biopharmaceutical company with R&D facilities in Hamilton, ON, that is developing a novel platform for engineering T cells to attack multiple cancer types.

CCAB is the assigned agent for the U of T for the commercialization of a large portfolio of human antibodies. Under the terms of the agreement, U of T will receive up-front fees, milestone payments and royalty payments on net sales of products on three therapeutic targets: BCMA, ROR1 and one undisclosed target.

“We are very pleased to be working with The Centre for the Commercialization of Antibodies and Biologics and the University of Toronto under this new licencing agreement,” said Paul Lammers, MD, MSc, President and Chief Executive Officer of Triumvira. “This partnership is critical as we work to bring new treatments to patients in need through our proprietary T Cell-Antigen Coupler (TAC) technology.”

Triumvira’s lead therapeutic candidate, TAC01-CD19, is a CD19-directed T cell product for the treatment of B cell malignancies and is anticipated to enter Phase I clinical trials in H1 2019 in patients with diffuse large B cell lymphoma (DLBCL). The company is also developing a series of products for solid tumors.

“Collaboration is a vital part in the development of new therapeutics. These types of agreements continue to strengthen the connection between academia and industry and help to translate the wealth of scientific knowledge from the laboratories at our world-class universities to the clinic,” CCAB Chief Executive Officer Robert Verhagen said.

About CCAB
The Centre for the Commercialization of Antibodies and Biologics (CCAB) is a national Centre of Excellence for Commercialization and Research located in Toronto, Canada. CCAB supports innovators and emerging life sciences companies through its expertise in product and business development to advance therapeutic candidates and technologies that will form the basis for company growth and sustainability. Visit CCAB’s website to learn more: ccabcanada.com

About Triumvira Immunologics
Triumvira Immunologics, Inc. is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., a niche life-sciences investment bank, with the vision of developing novel T cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with either solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, and our research facilities are in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to partners@triumvira.com

Contacts
CCAB Contact:
Karen Ramlall, +1 416-951-4663
Communications Manager
karen.ramlall@ccabcanada.com
or
Triumvira Contact:
LaVoieHealthScience
Katie Gallagher
Phone: +1-617-374-8800, Ext. 109
kgallagher@lavoiehealthscience.com

TAC technology shows efficacy, safety, and TAC-T cell persistence in preclinical models of liquid and solid tumors

AUSTIN, TX, and HAMILTON, ON, August 30, 2018 – Triumvira Immunologics, Inc. (Triumvira), a privately-held biopharmaceutical company focused on designing safe and more effective T cell therapies, will present data today on its novel T cell therapy technology, TAC-T, during an oral presentation in the Adoptive T Cell Therapies session of the 6th Annual Immuno-Oncology Summit held in Boston. The presentation will describe the differentiated mechanism of action of the company’s T cell antigen coupler (TAC) technology in preclinical studies demonstrating strong efficacy in both solid and liquid tumors with an improved safety profile compared to traditional CAR-T approaches.

The oral presentation, entitled: TAC-T: a novel T cell therapy, co-opts the endogenous T cell receptor for effective, safe, and persistent tumor rejection, will be delivered by Christopher Helsen, PhD, Director of Research and Development at Triumvira. Results from pre-clinical studies with human T cells engineered with Triumvira’s proprietary TAC technology directed against different antigens will be presented. The data suggest that TAC-T cells destroy tumor cells via a mechanism that mimics the natural process of T cell activation. Results clearly demonstrate efficient infiltration and proliferation in solid tumors resulting in rapid and sustained tumor regression in mice without toxicity. Furthermore, in a xenograft model of multiple myeloma, treated mice showed resistance to tumor re-challenge indicating long-term persistence of TAC-T cells.

“These results will further illustrate the potential of TAC-T cells, both in terms of efficacy and safety but also with respect to TAC T-cell persistence, a key point under consideration in T cell therapy,” said Paul Lammers, MD, MSc, President and Chief Executive Officer.

Triumvira also announces it is participating in the 11th Annual International Partnering Conference BioPharm America on September 5-6 and the 4th Annual CAR-TCR Summit 2018 – Changing Lives with CAR-T & TCR Cell Immunotherapies on September 4-5, both being held during Biotech Week Boston. For more information, or to set up a meeting with Triumvira at either conference email: partners@triumvira.com

About Triumvira Immunologics
Triumvira Immunologics, Inc. is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., a niche life-sciences investment bank, with the vision of developing novel T cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with either solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, and our research facilities in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to partners@triumvira.com

For more information:
LaVoieHealthScience
Katie Gallagher
Phone: +1-617-374-8800, Ext. 109
kgallagher@lavoiehealthscience.com

[/et_pb_text][et_pb_text _builder_version=”3.12.2″]

BCMA-TAC cells induce remission/ show persistence in Multiple Myeloma xenograft model (KMS11-NanoLuc)

click image for larger version